CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Callitas Health Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Callitas Health Inc
187 Pavilion Parkway, Suite 200
Phone: (859) 868-3131p:859 868-3131 NEWPORT, KY  41071  United States Ticker: MPHMFMPHMF
Business Summary
Callitas Health Inc. is a clinical-stage pharmaceutical development, over-the-counter (OTC) consumer goods marketing and cannabis delivery development company. The Company is focused on developing technologies for weight management, female sexual health and wellness, cannabis delivery technologies and other proprietary drugs. Its pharmaceutical/research and development pipeline includes C-103, which is a reformulation of Xenical (Orlistat 120 mg) for the treatment of obesity which minimizes adverse side effects associated with the use of Xenical, and Extrinsa, is a topical prescription gel that increases vaginal blood flow addressing female sexual dysfunction (FSD) issues. Extrinsa uses a combination of menthol/L-arginine and tadalafil (a PD5 inhibitor).

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202012/31/2019YesYes---

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
President, Chief Executive Officer JamesThompson 6/4/2018 1/3/2018
Chief Financial Officer GaryStephens 6/8/2017 6/8/2017
Director - Sales and Marketing JoshuaMaurice 10/25/2017 10/25/2017
4 additional Officers and Directors records available in full report.

Business Names
Business Name
40J’s LLC
LILY
M Diagnostics Inc.
9 additional Business Names available in full report.

General Information
Outstanding Shares: 45,271,962 (As of 9/30/2020)
Stock Exchange: OTC
Fax Number: (604) 428-0512


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, June 28, 2025